Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
about
MicroRNA-mediated drug resistance in ovarian cancer.A 4-miRNA signature to predict survival in glioblastomas.Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project.Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.
P2860
Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Clinical validation of chemoth ...... anel tested in ovarian cancer.
@ast
Clinical validation of chemoth ...... anel tested in ovarian cancer.
@en
type
label
Clinical validation of chemoth ...... anel tested in ovarian cancer.
@ast
Clinical validation of chemoth ...... anel tested in ovarian cancer.
@en
prefLabel
Clinical validation of chemoth ...... anel tested in ovarian cancer.
@ast
Clinical validation of chemoth ...... anel tested in ovarian cancer.
@en
P2093
P2860
P921
P1433
P1476
Clinical validation of chemoth ...... anel tested in ovarian cancer.
@en
P2093
Anker Hansen
Claus Høgdall
Guy Wayne Novotny
Ib Jarle Christensen
Kira Philipsen Prahm
Lotte Nedergaard
Mansoor Raza Mirza
Mona Aarenstrup Karlsen
Peter Buhl Jensen
Steen Knudsen
P2860
P304
P356
10.1371/JOURNAL.PONE.0174300
P407
P577
2017-03-23T00:00:00Z